(ZBH) Zimmer Biomet Holdings - Ratings and Ratios
Knee, Hip, Sports Medicine, Trauma, Craniomaxillofacial
Dividends
| Dividend Yield | 1.03% |
| Yield on Cost 5y | 0.71% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 96.8% |
| Payout Ratio | 11.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 25.2% |
| Value at Risk 5%th | 36.5% |
| Relative Tail Risk | -12.03% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.51 |
| Alpha | -22.45 |
| CAGR/Max DD | -0.23 |
| Character TTM | |
|---|---|
| Hurst Exponent | |
| Beta | 0.318 |
| Beta Downside | 0.302 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.66% |
| Mean DD | 19.91% |
| Median DD | 22.88% |
Description: ZBH Zimmer Biomet Holdings October 16, 2025
Zimmer Bioper (NYSE: ZBH) is a global medical-technology firm that designs, manufactures and markets a broad portfolio of orthopedic and reconstructive solutions-including knee and hip implants, sports-medicine devices, trauma and extremities products, and craniomaxillofacial/ thoracic fixation systems. Its offerings span hardware, bone-cement and data-driven surgical platforms that serve orthopedic surgeons, neurosurgeons, hospitals and specialty distributors worldwide.
In fiscal 2023 the company reported roughly $7.6 billion in revenue, with a 13 % operating margin-both modestly above the industry median of ~11 % for large orthopedic OEMs. Growth is being driven by three measurable levers: (1) an aging U.S. and European population that raises demand for joint replacement (U.S. joint-replacement procedures are projected to rise ~2 % annually through 2030); (2) expanding sales in emerging markets where per-capita orthopedic spend is still low but growing at ~8 % CAGR; and (3) incremental revenue from data-analytics services tied to its digital surgery platform, which now contributes ~3 % of total sales. A material risk is ongoing Medicare reimbursement pressure, which could compress margins if policy changes reduce payment rates for joint-replacement procedures.
For a deeper, data-driven assessment of ZBH’s valuation dynamics-including forward-looking cash-flow models and peer-adjusted multiples-explore the detailed analyst toolkit on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (805.2m TTM) > 0 and > 6% of Revenue (6% = 480.7m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 1.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 42.84% (prev 17.02%; Δ 25.82pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.69b > Net Income 805.2m (YES >=105%, WARN >=100%) |
| Net Debt (6.82b) to EBITDA (2.38b) ratio: 2.87 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (198.8m) change vs 12m ago -2.07% (target <= -2.0% for YES) |
| Gross Margin 71.44% (prev 71.78%; Δ -0.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 35.44% (prev 34.97%; Δ 0.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.61 (EBITDA TTM 2.38b / Interest Expense TTM 282.8m) >= 6 (WARN >= 3) |
Altman Z'' 4.05
| (A) 0.15 = (Total Current Assets 5.83b - Total Current Liabilities 2.40b) / Total Assets 23.49b |
| (B) 0.49 = Retained Earnings (Balance) 11.52b / Total Assets 23.49b |
| (C) 0.06 = EBIT TTM 1.30b / Avg Total Assets 22.60b |
| (D) 1.05 = Book Value of Equity 11.24b / Total Liabilities 10.72b |
| Total Rating: 4.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.23
| 1. Piotroski 7.0pt |
| 2. FCF Yield 6.32% |
| 3. FCF Margin 19.99% |
| 4. Debt/Equity 0.64 |
| 5. Debt/Ebitda 2.87 |
| 6. ROIC - WACC (= 0.22)% |
| 7. RoE 6.42% |
| 8. Rev. Trend 57.90% |
| 9. EPS Trend 43.93% |
What is the price of ZBH shares?
Over the past week, the price has changed by -4.47%, over one month by -9.71%, over three months by -10.86% and over the past year by -14.99%.
Is ZBH a buy, sell or hold?
- Strong Buy: 5
- Buy: 6
- Hold: 16
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the ZBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102.9 | 10.5% |
| Analysts Target Price | 102.9 | 10.5% |
| ValueRay Target Price | 87.7 | -5.9% |
ZBH Fundamental Data Overview November 26, 2025
P/E Trailing = 23.206
P/E Forward = 10.7759
P/S = 2.3136
P/B = 1.4321
P/EG = 0.9375
Beta = 0.61
Revenue TTM = 8.01b USD
EBIT TTM = 1.30b USD
EBITDA TTM = 2.38b USD
Long Term Debt = 7.51b USD (from longTermDebt, last quarter)
Short Term Debt = 600.0m USD (from shortTermDebt, last quarter)
Debt = 8.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.82b USD (from netDebt column, last quarter)
Enterprise Value = 25.35b USD (18.53b + Debt 8.11b - CCE 1.29b)
Interest Coverage Ratio = 4.61 (Ebit TTM 1.30b / Interest Expense TTM 282.8m)
FCF Yield = 6.32% (FCF TTM 1.60b / Enterprise Value 25.35b)
FCF Margin = 19.99% (FCF TTM 1.60b / Revenue TTM 8.01b)
Net Margin = 10.05% (Net Income TTM 805.2m / Revenue TTM 8.01b)
Gross Margin = 71.44% ((Revenue TTM 8.01b - Cost of Revenue TTM 2.29b) / Revenue TTM)
Gross Margin QoQ = 72.05% (prev 71.49%)
Tobins Q-Ratio = 1.08 (Enterprise Value 25.35b / Total Assets 23.49b)
Interest Expense / Debt = 0.93% (Interest Expense 75.4m / Debt 8.11b)
Taxrate = 17.19% (48.0m / 279.2m)
NOPAT = 1.08b (EBIT 1.30b * (1 - 17.19%))
Current Ratio = 2.43 (Total Current Assets 5.83b / Total Current Liabilities 2.40b)
Debt / Equity = 0.64 (Debt 8.11b / totalStockholderEquity, last quarter 12.76b)
Debt / EBITDA = 2.87 (Net Debt 6.82b / EBITDA 2.38b)
Debt / FCF = 4.26 (Net Debt 6.82b / FCF TTM 1.60b)
Total Stockholder Equity = 12.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.43% (Net Income 805.2m / Total Assets 23.49b)
RoE = 6.42% (Net Income TTM 805.2m / Total Stockholder Equity 12.54b)
RoCE = 6.51% (EBIT 1.30b / Capital Employed (Equity 12.54b + L.T.Debt 7.51b))
RoIC = 5.46% (NOPAT 1.08b / Invested Capital 19.80b)
WACC = 5.24% (E(18.53b)/V(26.65b) * Re(7.19%) + D(8.11b)/V(26.65b) * Rd(0.93%) * (1-Tc(0.17)))
Discount Rate = 7.19% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.38%
[DCF Debug] Terminal Value 78.61% ; FCFE base≈1.46b ; Y1≈1.49b ; Y5≈1.66b
Fair Price DCF = 147.2 (DCF Value 29.18b / Shares Outstanding 198.2m; 5y FCF grow 2.13% → 3.0% )
EPS Correlation: 43.93 | EPS CAGR: -0.69% | SUE: 0.69 | # QB: 0
Revenue Correlation: 57.90 | Revenue CAGR: -0.48% | SUE: -0.89 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.92 | Chg30d=-0.003 | Revisions Net=+3 | Analysts=19
EPS next Year (2026-12-31): EPS=8.52 | Chg30d=-0.051 | Revisions Net=-4 | Growth EPS=+4.3% | Growth Revenue=+5.2%
Additional Sources for ZBH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle